Global Business Report interviews IBSA Farmaceutici
Waiting for the next CPhI worldwide, a congress dedicated to the pharmaceutical field on stage in Milan from 9 to 11 November, GBR, the international magazine dedicated to the business world and decision makers, tells the impact and the great value that IBSA creates.
Through the excellent job of its People and its consolidated experience, IBSA invests in innovation and technologies and thanks to its production capacity is characterized as a reliable player for the growth of the international pharmaceutical market.
Luca Crippa, Ceo & Managing Director of IBSA Farmaceutici, told GBR the story, which began 40 years ago in a small Swiss laboratory. IBSA stands for Institut Biochimique SA and it started as a small Swiss laboratory in Lugano 40 years ago. Under the visionary leadership of its founder, Arturo Licenziati, IBSA transformed into a global company, active in 10 therapeutic areas with a reach in more than 80 countries. Luca Crippa emphasized the importance of the 4 pillars that guide the group’s work – Person, Innovation, Quality and Responsibility – as well as the critical role the Person and her needs have as an inspiration and, at the same time, as the objective of the path undertaken by IBSA.
During the interview, Luca Crippa presented the peculiarities of IBSA Farmaceutici, underlining the unstoppable commitment – even in a pandemic period – that the company continues to pursue to make a concrete contribution to the health system of our Country, through an investment plan for the technological improvement and the expansion of production. IBSA Farmaceutici also promotes all over the world the know-how and the “made in Italy of excellence”, developing in-house technologies that serve all the global markets in which IBSA operates.
